Abbott results beat on medical device boost, Exact deal hits forecast

Reuters

Thu, April 16, 2026 astatine 6:40 AM CDT 1 min read

April 16 (Reuters) - Abbott marginally bushed Wall Street estimates for quarterly nett and ‌revenue connected Thursday, partially helped ‌by its recently acquired crab diagnostics business.

However, its shares ​were down 2% earlier the bell, aft the institution said its 2026 nett forecast volition spot a 20 cent deed owed ‌to its caller $23 ⁠billion acquisition of crab trial shaper Exact Sciences.

The aesculapian instrumentality shaper ⁠expects adjusted nett per stock betwixt $5.38 to $5.58 for 2026, compared with its erstwhile ​forecast of $5.55 ​to $5.80 per share.

Despite ​the hit, CEO Robert ‌Ford said the acquisition of Exact Sciences adds different high-growth concern to the company's portfolio.

The institution besides benefited from continued spot successful its aesculapian instrumentality unit, its ‌largest successful presumption of ​revenue.

On an adjusted basis, the ​company reported ​first-quarter nett per stock of $1.15, ‌compared with analysts' estimation ​of $1.14, according ​to information compiled by LSEG.

Total gross came successful astatine $11.16 cardinal successful the archetypal ​quarter, compared ‌with expectations of $11 billion.

(Reporting by Siddhi ​Mahatole and Puyaan Singh successful Bengaluru; ​Editing by Devika Syamnath)